April 16, 2016
The company claims that the pharmaceutical composition in the product, related to multiple sclerosis drug Laquinimod, provides superior stabilisation
Israel-based Teva Pharmaceuticals has received patent approval for a product related to multiple sclerosis drug Laquinimod. According to reports, Laquinimod is developed by Teva Pharma in collaboration with Active Biotech AB, a Swedish biotechnology company which has focus on neurodegenerative/ inflammatory diseases and cancer.
According to Active Biotech, laquinimod is a compound under development for the treatment of multiple sclerosis and Huntington’s disease and the company has an agreement with Teva covering the development and commercialisation of the drug.
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
MS Views and News
Providing educational information and resources for those affected by MS
Keep current with Multiple Sclerosis news and information
To opt-in (sign-up) at our website: click here – thank you
.===================================
Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews